title: Myoclonus and transcranial magnetic stimulation.
abstract: The neural dysfunction at the origin of myoclonus may locate at various anatomical levels within the central nervous system, including the motor cortices. Transcranial magnetic stimulation (TMS) can be used to assess the balance between inhibitory and excitatory processes involved in the regulation of motor cortex activity and thereby, may be of value to determine the pathophysiological mechanisms of myoclonus. Using paired-pulse paradigms with various interstimulus intervals, TMS studies showed that intracortical inhibition (ICI) was reduced in progressive myoclonic epilepsy (PME). In contrast, ICI was decreased only for short interstimulus intervals in patients with juvenile myoclonic epilepsy (JME). Transcallosal inhibition and sensorimotor integration were also both altered in PME but not in JME. Actually, the loss of inhibitory regulation within the central nervous system might represent an intrinsic mechanism of myoclonus, whether of epileptic origin or not. Finally, the other TMS parameters of excitability (motor threshold, silent period, intracortical facilitation) were found normal in most cases of myoclonus. According to these observations, it was quite conceivable that the application of repetitive trains of TMS (rTMS) at inhibitory low-frequency (around 1 Hz) might be able to relieve myoclonus by restoring ICI. A few reported cases illustrate the efficacy of low-frequency rTMS to alleviate myoclonic symptoms. Therapeutic-like perspectives are opened for rTMS in these forms of myoclonus that are related to motor cortical hyperexcitability secondary to the loss of ICI.
authors.affiliation: Service de physiologie, explorations fonctionnelles, hôpital Henri-Mondor, Assistance publique-Hôpitaux de Paris, 51, avenue du Marechal-Lattre-de-Tassigny, 94010 Créteil, France. jean-pascal.lefaucheur@hmn.aphp.fr
authors.forename: J-P
authors.initials: JP
authors.lastname: Lefaucheur
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use; D004831:Epilepsies, Myoclonic / Q000628:therapy; D005071:Evoked Potentials; D006801:Humans; D009044:Motor Cortex / Q000503:physiopathology*; D020191:Myoclonic Epilepsies, Progressive / Q000188:drug therapy / Q000503:physiopathology*; D020190:Myoclonic Epilepsy, Juvenile / Q000188:drug therapy / Q000503:physiopathology*; D009207:Myoclonus / Q000503:physiopathology*; D050781:Transcranial Magnetic Stimulation
chemical_list: D000927:Anticonvulsants